氟菜西罗沙 | 98205-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 氟菜西罗沙
• 英文名称: Flesinoxan hydrochloride
• 英文别名: 4-fluoro-N-[2-[4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl]ethyl]benzamide;hydrochloride
• CAS: 98205-89-1
• 化学式: C22H27ClFN3O4
• 分子量: 451.9
• InChiKey: LZBWQEXVQZCBDJ-FERBBOLQSA-N

物化性质

• 熔点：
  184.5-185.5°; mp 183.0-184.0° (Ennis)
• 比旋光度：
  D +25° (c = 1 in methanol)

计算性质

• 辛醇/水分配系数(LogP)：
  1.93
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  74.3
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Substantially pure hetero-bicyclic alcohol enantiomers
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0939135A1

  公开（公告）日：1999-09-01

  The invention relates to substantially pure hetero-bicyclic alcohol enantiomers of the formula I, III, and IV wherein X is O, S, NH, N-(C1-C4)alkyl or CH2; Y1, Y2 and Y3 are each independently hydrogen or substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4-haloalkyl, nitro and cyano; the NO2 substituent is attached to the bicyclic ring system in the 5- or 7-position; and the C*-atom has either the R configuration. The invention also relates to the use of said enantiomers for the preparation of a pharmacologically active piperazine derivative.

  本发明涉及式 I、III 和 IV 的基本纯杂环醇对映体 其中 X 是 O、S、NH、N-(C1-C4)烷基或 CH2； Y1、Y2 和 Y3 各自独立地为氢或选自卤素、C1-C4 烷基、C1-C4 烷氧基、C1-C4-卤代烷基、硝基和氰基的取代基； NO2 取代基连接到双环系统的 5 位或 7 位上 5 位或 7 位连接到双环系统上；以及 C* 原子具有 R 构型。 本发明还涉及使用上述对映体制备具有药理活性的哌嗪衍生物。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• Ion-strength independent sustained release pharmaceutical formulation
  申请人：——

  公开号：US20040013727A1

  公开（公告）日：2004-01-22

  The present invention is related to an optionally coated pharmaceutical hydrophilic gel foaming matrix formulation comprising one or more active substances and having a prolonged release of said one or more active substances upon exposure to gastrointestinal fluids, characterized in that said release is substantially ion-strength independent. The invention is further related to a method of preparing this formulation which can be used in the administration of active substances for the treatment of a large number of disorders.

  本发明涉及一种可选包衣的药用亲水凝胶发泡基质制剂，该制剂包含一种或多种活性物质，并且在暴露于胃肠液时可延长所述一种或多种活性物质的释放，其特征在于所述释放基本上与离子强度无关。本发明还涉及一种制备该制剂的方法，该方法可用于施用活性物质治疗多种疾病。
• Enzymatic process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0605033B1

  公开（公告）日：1999-07-21
• ION-STRENGTH INDEPENDENT SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1345595A1

  公开（公告）日：2003-09-24